CJC-1295 DAC
CJC-1295 DAC
Crypto
Restock in progress. Add your email and we will tell you the moment this compound is back in stock.
One email when this is back in stock. No spam, unsubscribe anytime.
Product details
CJC-1295 DAC is a synthetic analog of growth hormone-releasing hormone (GHRH), built on the GRF(1-29) backbone and carrying a Drug Affinity Complex (DAC) modification. It belongs to the GHRH analog peptide class.
In the published preclinical literature, CJC-1295 DAC has been characterised at the molecular level as a long-acting agonist at the GHRH receptor on the anterior pituitary, with the DAC modification studied for its covalent binding to circulating serum albumin and the resulting extension of plasma residence time in animal models. It is supplied as a research compound and is not intended for human or veterinary use.
Full specifications
Complete your order
supplied for laboratory research only
Recently viewed
picks up where you left off
Research
CJC-1295 DAC has been characterised in preclinical laboratory models. The primary studies below, in cultured rat pituitary cells and in animal models, examined receptor agonism, serum-albumin conjugation, plasma persistence, and endpoints across the growth hormone and IGF-1 axis. The literature is preclinical; it describes the compound, not any outcome in humans.
2 preclinical studies indexed · ghrh receptor and animal models · links open on PubMed
GHRH receptor and animal models 2 studies
Animal and in vitro
GRF(1-29)-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats, identifying CJC-1295 as a long-acting GRF analog
In cultured rat anterior pituitary cells and in rats, the study assayed GRF-receptor agonist binding and growth hormone secretion, confirmed covalent conjugation of the bioconjugate to circulating serum albumin, and measured plasma persistence beyond 72 hours as a pharmacokinetic endpoint.
Read the study ↗
Animal model
A long-acting GHRH analog dosed once daily in the GHRH-knockout mouse model
In a GHRH-knockout mouse model dosed at 24, 48, and 72 hour intervals over five weeks, the study measured pituitary and circulating endpoints across the growth hormone and IGF-1 axis as a function of the long-acting GHRH analog and its dosing interval.
Read the study ↗
Links open the original study on PubMed. For research and educational purposes, descriptive of the published preclinical literature, not therapeutic claims about any ai-peptides product. A Certificate of Analysis and a Safety Data Sheet are available on request for every batch.
Reviews
Verified-order reviews on service, shipping, and product quality appear here once the first order is reviewed.